Francesca Crovetto1,2,3,4, Fàtima Crispi1,3,4, Elisa Llurba5,6, Rosalia Pascal1,6, Marta Larroya1, Cristina Trilla5, Marta Camacho1, Carmen Medina5, Carlota Dobaño7, Maria Dolores Gomez-Roig1,2,6, Francesc Figueras1,3, Eduard Gratacos1,2,3,4. 1. Department of Maternal-Fetal Medicine, BCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Sant Joan de Déu and Hospital Clínic, Universitat de Barcelona, Barcelona, Spain. 2. Institut de Recerca Sant Joan de Deu, Barcelona, Spain. 3. Institut de Recerca August Pi Sunyer, Barcelona, Spain. 4. Center for Biomedical Network Research on Rare Diseases. Barcelona, Spain. 5. Department of Obstetrics and Gynaecology, Hospital de la Santa Creu i de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. 6. Maternal and Child Health and Development Network, Instituto de Salud Carlos III, Barcelona, Spain. 7. ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
Abstract
BACKGROUND: A population-based study to describe the impact of SARS-CoV-2 infection on pregnancy outcomes. METHODS: Prospective, population-based study including pregnant women consecutively attended at first/second trimester or at delivery at three hospitals in Barcelona, Spain. SARS-CoV-2 antibodies (IgG and IgM/IgA) were measured in all participants and nasopharyngeal RT-PCR was performed at delivery. The primary outcome was a composite of pregnancy complications in SARS-CoV-2 positive versus negative women: miscarriage, preeclampsia, preterm delivery, perinatal death, small-for-gestational age, neonatal admission. Secondary outcomes were components of the primary outcome plus abnormal fetal growth, malformation, intrapartum fetal distress. Outcomes were also compared between positive symptomatic and positive asymptomatic SARS-CoV-2 women. RESULTS: Of 2,225 pregnant women, 317 (14.2%) were positive for SARS-CoV-2 antibodies (n=314, 99.1%) and/or RT-PCR (n=36, 11.4%). Among positive women, 217 (68.5%) were asymptomatic, 93 (29.3%) had mild COVID-19 and 7 (2.2%) pneumonia, of which 3 required intensive care unit admission. In women with and without SARS-CoV-2 infection, the primary outcome occurred in 43 (13.6%) and 268 (14%), respectively [risk difference -0.4%, (95% CI: -4.1% to 4.1)]. As compared with non-infected women, women with symptomatic COVID-19 had increased rates of preterm delivery (7.2% vs. 16.9%, p=0.003) and intrapartum fetal distress (9.1% vs. 19.2%, p=0.004), while asymptomatic women had similar rates to non-infected cases. Among 143 fetuses from infected mothers, none had anti-SARS-CoV-2 IgM/IgA in cord blood. CONCLUSIONS: The overall rate of pregnancy complications in women with SARS-CoV-2 infection was similar to non-infected women. However, symptomatic COVID-19 was associated with modest increases in preterm delivery and intrapartum fetal distress.
BACKGROUND: A population-based study to describe the impact of SARS-CoV-2 infection on pregnancy outcomes. METHODS: Prospective, population-based study including pregnant women consecutively attended at first/second trimester or at delivery at three hospitals in Barcelona, Spain. SARS-CoV-2 antibodies (IgG and IgM/IgA) were measured in all participants and nasopharyngeal RT-PCR was performed at delivery. The primary outcome was a composite of pregnancy complications in SARS-CoV-2 positive versus negative women: miscarriage, preeclampsia, preterm delivery, perinatal death, small-for-gestational age, neonatal admission. Secondary outcomes were components of the primary outcome plus abnormal fetal growth, malformation, intrapartum fetal distress. Outcomes were also compared between positive symptomatic and positive asymptomatic SARS-CoV-2women. RESULTS: Of 2,225 pregnant women, 317 (14.2%) were positive for SARS-CoV-2 antibodies (n=314, 99.1%) and/or RT-PCR (n=36, 11.4%). Among positive women, 217 (68.5%) were asymptomatic, 93 (29.3%) had mild COVID-19 and 7 (2.2%) pneumonia, of which 3 required intensive care unit admission. In women with and without SARS-CoV-2 infection, the primary outcome occurred in 43 (13.6%) and 268 (14%), respectively [risk difference -0.4%, (95% CI: -4.1% to 4.1)]. As compared with non-infectedwomen, women with symptomatic COVID-19 had increased rates of preterm delivery (7.2% vs. 16.9%, p=0.003) and intrapartum fetal distress (9.1% vs. 19.2%, p=0.004), while asymptomatic women had similar rates to non-infected cases. Among 143 fetuses from infected mothers, none had anti-SARS-CoV-2 IgM/IgA in cord blood. CONCLUSIONS: The overall rate of pregnancy complications in women with SARS-CoV-2 infection was similar to non-infectedwomen. However, symptomatic COVID-19 was associated with modest increases in preterm delivery and intrapartum fetal distress.
Authors: Luciana C Delamuta; Pedro A A Monteleone; Edson S Ferreira-Filho; Vanessa Heinrich-Oliveira; José Maria Soares-Júnior; Edmund C Baracat; Gustavo A R Maciel Journal: Clinics (Sao Paulo) Date: 2021-09-06 Impact factor: 2.365
Authors: Sarah Geoghegan; Laura C Stephens; Kristen A Feemster; Richard J Drew; Maeve Eogan; Karina M Butler Journal: Hum Vaccin Immunother Date: 2021-05-19 Impact factor: 3.452
Authors: Valeria Garcia-Flores; Roberto Romero; Yi Xu; Kevin Theis; Marcia Arenas-Hernandez; Derek Miller; Azam Peyvandipour; Jose Galaz; Dustyn Levenson; Gaurav Bhatti; Meyer Gershater; Errile Pusod; David Kracht; Violetta Florova; Yaozhu Leng; Li Tao; Megan Faucett; Robert Para; Chaur-Dong Hsu; Gary Zhang; Adi L Tarca; Roger Pique-Regi; Nardhy Gomez-Lopez Journal: Res Sq Date: 2021-03-31